Literature DB >> 19337196

Signaling networks associated with BCR-ABL-dependent transformation.

Lori A Hazlehurst1, Nadine N Bewry, Rajesh R Nair, Javier Pinilla-Ibarz.   

Abstract

BACKGROUND: The fusion protein BCR-ABL results in constitutive tyrosine kinase activity. It also affects downstream targets as well as the subcellular location of the normally tightly regulated Abl tyrosine kinase.
METHODS: The authors review the current knowledge concerning the signaling networks associated with BCR-ABL-dependent transformation.
RESULTS: Although BCR-ABL is considered a single genetic change, the dysregulated tyrosine kinase activates a network of signals that contributes to cytokine-independent growth, resistance to apoptosis, and genetic instability.
CONCLUSIONS: The effectiveness of BCR-ABL-dependent transformation of hematopoietic stem cells is due not to a single pathway but rather to the culmination of a network of signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337196     DOI: 10.1177/107327480901600202

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  23 in total

1.  Liquid crystal-related compound-induced cell growth suppression and apoptosis in the chronic myelogenous leukemia K562 cell line.

Authors:  Yukako Fukushi; Masaharu Hazawa; Kenji Takahashi; Atsushi Yoshizawa; Ikuo Kashiwakura
Journal:  Invest New Drugs       Date:  2010-04-27       Impact factor: 3.850

2.  Caspase-independent apoptosis induction of quorum-sensing autoinducer analogs against chronic myeloid leukemia K562.

Authors:  Masaharu Hazawa; Michiko Kudo; Toshihiro Iwata; Kazuki Saito; Kenji Takahashi; Jun Igarashi; Hiroaki Suga; Ikuo Kashiwakura
Journal:  Invest New Drugs       Date:  2011-01-05       Impact factor: 3.850

3.  Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.

Authors:  Elie Traer; Nathalie Javidi-Sharifi; Anupriya Agarwal; Jennifer Dunlap; Isabel English; Jacqueline Martinez; Jeffrey W Tyner; Melissa Wong; Brian J Druker
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

4.  Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation.

Authors:  Jun Lee; Guobing Zhang; Xiuhua Wu; Feilong Xu; Jun Zhou; Xingguo Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-26       Impact factor: 4.553

5.  Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.

Authors:  Andrew S Dixon; Geoffrey D Miller; Benjamin J Bruno; Jonathan E Constance; David W Woessner; Trevor P Fidler; James C Robertson; Thomas E Cheatham; Carol S Lim
Journal:  Mol Pharm       Date:  2011-12-12       Impact factor: 4.939

6.  Assessment of interleukin 1β serum level in different responder groups and stages of chronic myeloid leukemia patients on imatinb mesylate therapy.

Authors:  Bassam Francis Matti; Maysoon Ali Saleem; Shahla'a Fadhil Sabir
Journal:  Indian J Hematol Blood Transfus       Date:  2014-02-07       Impact factor: 0.900

7.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

8.  Multidomain targeting of Bcr-Abl by disruption of oligomerization and tyrosine kinase inhibition: toward eradication of CML.

Authors:  Geoffrey D Miller; David W Woessner; Monika J Sirch; Carol S Lim
Journal:  Mol Pharm       Date:  2013-08-20       Impact factor: 4.939

Review 9.  Nilotinib: a novel, selective tyrosine kinase inhibitor.

Authors:  Jean-Yves Blay; Margaret von Mehren
Journal:  Semin Oncol       Date:  2011-04       Impact factor: 4.929

10.  Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.

Authors:  Ting Song; Yafei Guo; Zuguang Xue; Zongwei Guo; Ziqian Wang; Donghai Lin; Hong Zhang; Hao Pan; Xiaodong Zhang; Fangkui Yin; Hang Wang; Laura Bonnette Uwituze; Zhichao Zhang
Journal:  Leukemia       Date:  2021-05-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.